|
|
|
|
LEADER |
04814nma a2201669 u 4500 |
001 |
EB002039264 |
003 |
EBX01000000000000001182930 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
220822 ||| eng |
020 |
|
|
|a 9783036533049
|
020 |
|
|
|a books978-3-0365-3303-2
|
020 |
|
|
|a 9783036533032
|
100 |
1 |
|
|a Facchiano, Antonio
|
245 |
0 |
0 |
|a Advances and Novel Treatment Options in Metastatic Melanoma
|h Elektronische Ressource
|
260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
300 |
|
|
|a 1 electronic resource (528 p.)
|
653 |
|
|
|a radiotherapy
|
653 |
|
|
|a pembrolizumab
|
653 |
|
|
|a machine learning
|
653 |
|
|
|a melanoma markers
|
653 |
|
|
|a interferon
|
653 |
|
|
|a nivolumab
|
653 |
|
|
|a BCL2L10
|
653 |
|
|
|a nicotinic receptors
|
653 |
|
|
|a amoeboid motility
|
653 |
|
|
|a tumor microenvironment
|
653 |
|
|
|a combined therapy
|
653 |
|
|
|a ML258
|
653 |
|
|
|a cell therapy
|
653 |
|
|
|a melanomagenesis
|
653 |
|
|
|a HIPPO
|
653 |
|
|
|a targeted-therapy
|
653 |
|
|
|a cancer associated fibroblast
|
653 |
|
|
|a melanoma immune infiltrate
|
653 |
|
|
|a immunotherapy
|
653 |
|
|
|a Support Vector Machine
|
653 |
|
|
|a motility
|
653 |
|
|
|a liquid biopsy
|
653 |
|
|
|a therapy
|
653 |
|
|
|a OXPHOS
|
653 |
|
|
|a Rac1
|
653 |
|
|
|a CXCL10
|
653 |
|
|
|a cholinergic system
|
653 |
|
|
|a patient stratification
|
653 |
|
|
|a WNT5A
|
653 |
|
|
|a metastatic uveal melanoma (mUM)
|
653 |
|
|
|a MARCKS
|
653 |
|
|
|a cancer
|
653 |
|
|
|a prognosis
|
653 |
|
|
|a plasmacytoid dendritic cells
|
653 |
|
|
|a SOCE
|
653 |
|
|
|a prediction
|
653 |
|
|
|a BRAF-mutant melanoma
|
653 |
|
|
|a TLR
|
653 |
|
|
|a ABT-737
|
653 |
|
|
|a melanoma
|
653 |
|
|
|a sex/gender
|
653 |
|
|
|a uveal melanoma (UM)
|
653 |
|
|
|a checkpoint inhibitor
|
653 |
|
|
|a BRAF
|
653 |
|
|
|a prognostication
|
653 |
|
|
|a nanoparticles
|
653 |
|
|
|a PD-1
|
653 |
|
|
|a melanoma metastasis
|
653 |
|
|
|a ipilimumab
|
653 |
|
|
|a acetazolamide
|
653 |
|
|
|a metastases
|
653 |
|
|
|a invasion
|
653 |
|
|
|a DOCK4
|
653 |
|
|
|a cytotoxicity
|
653 |
|
|
|a cancer stem cells
|
653 |
|
|
|a targeted therapy
|
653 |
|
|
|a metastatic therapy
|
653 |
|
|
|a Medicine and Nursing / bicssc
|
653 |
|
|
|a muscarinic receptors
|
653 |
|
|
|a MITF
|
653 |
|
|
|a protein tyrosine phosphatase
|
653 |
|
|
|a FAK
|
653 |
|
|
|a therapeutic resistance
|
653 |
|
|
|a resistance
|
653 |
|
|
|a mucosal melanoma
|
653 |
|
|
|a immunity
|
653 |
|
|
|a microenvironment
|
653 |
|
|
|a arthralgia
|
653 |
|
|
|a angiogenesis
|
653 |
|
|
|a hedgehog
|
653 |
|
|
|a n/a
|
653 |
|
|
|a phosphorylation
|
653 |
|
|
|a diagnosis
|
653 |
|
|
|a exosomes
|
653 |
|
|
|a mechanism of action
|
653 |
|
|
|a metastatic dormancy
|
653 |
|
|
|a sex-hormones
|
653 |
|
|
|a metalloproteinases
|
653 |
|
|
|a cytokines
|
653 |
|
|
|a BRAF inhibitors
|
653 |
|
|
|a drug resistance
|
653 |
|
|
|a microRNAs
|
653 |
|
|
|a tumour microenvironment
|
653 |
|
|
|a ctDNA
|
653 |
|
|
|a siRNA
|
653 |
|
|
|a liver-directed-therapies
|
653 |
|
|
|a STAT3
|
653 |
|
|
|a essential oils
|
653 |
|
|
|a rheumatoid arthritis
|
653 |
|
|
|a TPC2
|
653 |
|
|
|a adjuvant therapy
|
653 |
|
|
|a principal component analysis
|
653 |
|
|
|a apoptosis
|
653 |
|
|
|a MANS peptide
|
653 |
|
|
|a biomarkers
|
653 |
|
|
|a small molecules
|
653 |
|
|
|a ShcD adaptor protein
|
653 |
|
|
|a target therapy
|
653 |
|
|
|a acetylcholine
|
653 |
|
|
|a survival
|
653 |
|
|
|a slow cycling phenotype
|
653 |
|
|
|a Bcl-2 family
|
653 |
|
|
|a metastasis
|
653 |
|
|
|a extracellular vesicles
|
653 |
|
|
|a cyclopamine
|
653 |
|
|
|a carbonic anhydrase
|
653 |
|
|
|a lactate dehydrogenase
|
653 |
|
|
|a lipid metabolism
|
653 |
|
|
|a melanoma PDX
|
653 |
|
|
|a PTPs inhibitors
|
653 |
|
|
|a HuR
|
653 |
|
|
|a BRAF inhibitor
|
700 |
1 |
|
|a Del Bufalo, Donatella
|
700 |
1 |
|
|a Carè, Alessandra
|
700 |
1 |
|
|a Facchiano, Antonio
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
024 |
8 |
|
|a 10.3390/books978-3-0365-3303-2
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/79644
|z DOAB: description of the publication
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5029
|7 0
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 363
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 700
|
520 |
|
|
|a The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
|